uniQure (NASDAQ:QURE) Stock Rating Raised to "Hold" at Wall Street Zen

uniQure logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded uniQure from “Sell” to “Hold.” Despite the upgrade, analyst views remain mostly positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $56.83.
  • Recent ratings were mixed: William Blair issued a “Strong Buy,” while Goldman Sachs cut its price target from $46 to $31 and assigned a “Neutral” rating.
  • uniQure reported quarterly adjusted losses of $0.88 per share, beating estimates of $0.92 in losses, but revenue of $5.2 million fell short of the $6.17 million consensus.
  • Five stocks to consider instead of uniQure.

uniQure (NASDAQ:QURE - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other brokerages have also recently commented on QURE. William Blair raised shares of uniQure to a "strong-buy" rating in a research report on Wednesday, September 23rd. HC Wainwright reissued a "buy" rating on shares of uniQure in a research report on Tuesday, September 29th. Wells Fargo & Company restated an "overweight" rating and set a $75.00 price objective on shares of uniQure in a research note on Tuesday, September 29th. Stifel Nicolaus set a $71.00 price target on uniQure in a report on Wednesday. Finally, The Goldman Sachs Group dropped their target price on shares of uniQure from $46.00 to $31.00 and set a "neutral" rating on the stock in a report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, uniQure presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.83.

View Our Latest Analysis on uniQure

uniQure Stock Up 3.3%

Shares of QURE opened at $21.70 on Friday. The company has a 50-day moving average of $31.86 and a two-hundred day moving average of $29.68. The company has a current ratio of 10.01, a quick ratio of 10.01 and a debt-to-equity ratio of 0.15. uniQure has a one year low of $8.73 and a one year high of $51.72.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.04. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The company had revenue of $5.20 million during the quarter, compared to analysts' expectations of $6.17 million. As a group, equities analysts anticipate that uniQure will post -3.81 earnings per share for the current year.

Hedge Funds Weigh In On uniQure

A number of large investors have recently added to or reduced their stakes in QURE. Privium Fund Management B.V. purchased a new position in uniQure during the third quarter worth approximately $5,223,000. Pekin Hardy Strauss Inc. grew its position in uniQure by 63.3% in the 3rd quarter. Pekin Hardy Strauss Inc. now owns 153,890 shares of the biotechnology company's stock worth $3,718,000 after purchasing an additional 59,640 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in uniQure in the 3rd quarter worth about $86,000. China Universal Asset Management Co. Ltd. bought a new stake in uniQure in the third quarter valued at about $310,000. Finally, Maxi Investments CY Ltd bought a new position in uniQure during the 3rd quarter worth approximately $966,000. 78.83% of the stock is currently owned by institutional investors.

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure's best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.

Featured Stories

Analyst Recommendations for uniQure (NASDAQ:QURE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in uniQure Right Now?

Before you consider uniQure, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.

While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines